142 related articles for article (PubMed ID: 19601745)
1. 17alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: a review.
Owen CP
Anticancer Agents Med Chem; 2009 Jul; 9(6):613-26. PubMed ID: 19601745
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
Leroux F
Curr Med Chem; 2005; 12(14):1623-9. PubMed ID: 16022662
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, 17α-hydroxylase-C
Banday AH; Shameem SA; Banday JA; Ganaie BA
Anticancer Agents Med Chem; 2018; 18(13):1919-1926. PubMed ID: 29697032
[TBL] [Abstract][Full Text] [Related]
4. CYP17A1: a biochemistry, chemistry, and clinical review.
Porubek D
Curr Top Med Chem; 2013; 13(12):1364-84. PubMed ID: 23688130
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of CYP 17, a new strategy for the treatment of prostate cancer.
Hartmann RW; Ehmer PB; Haidar S; Hector M; Jose J; Klein CD; Seidel SB; Sergejew TF; Wachall BG; Wächter GA; Zhuang Y
Arch Pharm (Weinheim); 2002 Apr; 335(4):119-28. PubMed ID: 12112031
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of steroidal cytochrome p450 enzymes as targets for drug development.
Baston E; Leroux FR
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):31-58. PubMed ID: 18221052
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer.
Njar VC; Brodie AM
Curr Pharm Des; 1999 Mar; 5(3):163-80. PubMed ID: 10066888
[TBL] [Abstract][Full Text] [Related]
8. [Advances in the study of steroidal inhibitors of cytochrome P45017alpha].
Du JJ; Chen HL; Li YC
Yao Xue Xue Bao; 2013 Jan; 48(1):25-31. PubMed ID: 23600137
[TBL] [Abstract][Full Text] [Related]
9. Computational prediction of new CYP17 inhibitors based on pharmacophore modeling, virtual screening and docking approach.
Haidar S; Hartmann RW
Pharmazie; 2017 Sep; 72(9):529-536. PubMed ID: 29441980
[TBL] [Abstract][Full Text] [Related]
10. CYP17 inhibitors for prostate cancer treatment--an update.
Moreira VM; Salvador JA; Vasaitis TS; Njar VC
Curr Med Chem; 2008; 15(9):868-99. PubMed ID: 18473796
[TBL] [Abstract][Full Text] [Related]
11. Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
Guengerich FP; McCarty KD; Chapman JG; Tateishi Y
J Biol Chem; 2021 Aug; 297(2):100969. PubMed ID: 34273352
[TBL] [Abstract][Full Text] [Related]
12. Environmental inhibitors of the expression of cytochrome P450 17A1 in mammals.
Peng Z; Xueb G; Chen W; Xia S
Environ Toxicol Pharmacol; 2019 Jul; 69():16-25. PubMed ID: 30921671
[TBL] [Abstract][Full Text] [Related]
13. Targeting CYP17: established and novel approaches in prostate cancer.
Yap TA; Carden CP; Attard G; de Bono JS
Curr Opin Pharmacol; 2008 Aug; 8(4):449-57. PubMed ID: 18619560
[TBL] [Abstract][Full Text] [Related]
14. Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases.
Salvador JA; Pinto RM; Silvestre SM
J Steroid Biochem Mol Biol; 2013 Sep; 137():199-222. PubMed ID: 23688836
[TBL] [Abstract][Full Text] [Related]
15. P450-dependent enzymes as targets for prostate cancer therapy.
De Coster R; Wouters W; Bruynseels J
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
[TBL] [Abstract][Full Text] [Related]
16. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
Rafferty SW; Eisner JR; Moore WR; Schotzinger RJ; Hoekstra WJ
Bioorg Med Chem Lett; 2014 Jun; 24(11):2444-7. PubMed ID: 24775307
[TBL] [Abstract][Full Text] [Related]
17. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
[TBL] [Abstract][Full Text] [Related]
18. CYP17 inhibitors for prostate cancer therapy.
Vasaitis TS; Bruno RD; Njar VC
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):23-31. PubMed ID: 21092758
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2.
Hartmann RW; Hector M; Haidar S; Ehmer PB; Reichert W; Jose J
J Med Chem; 2000 Nov; 43(22):4266-77. PubMed ID: 11063622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]